Kazia Therapeutics Limited
Kazia Therapeutics Limited (KZIA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · KZIA · as of Dec 31, 2024
Ownership Breakdown
12
Institutional Holders
▼ 6 vs Q3
$569,091
Total Inst. Value
▼ $346,336 vs Q3
1.62M
Shares Outstanding
freeFloat 98.57%
321,669
13F Shares Held
▼ 1.81M vs Q3
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
KZIA largest shareholders · institutional ownership
Q4 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
MAI CAPITAL MANAGEMENT pharmaceutical preparations | 139.2K | 3.27% | 3.27% | $246.40M | Feb 14, 2025 | NEW |
BARCLAYS PLC pharmaceutical preparations | 120.0K | 2.82% | 2.82% | $212.40M | Mar 19, 2026 | NEW |
UBS GROUP AG pharmaceutical preparations | 27.5K | 64.80% | 64.80% | $48.76M | Feb 14, 2025 | NEW |
MORGAN STANLEY pharmaceutical preparations | 23.4K | 55.14% | 55.14% | $41.49M | May 15, 2025 | NEW |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 13.4K | 31.52% | 31.52% | $23.72M | Feb 14, 2025 | NEW |
JPMORGAN CHASE & CO pharmaceutical preparations | 7.2K | 16.95% | 16.95% | $12.75M | Feb 12, 2025 | NEW |
RHUMBLINE ADVISERS pharmaceutical preparations | 2.8K | 6.53% | 6.53% | $4.91M | May 29, 2025 | NEW |
CITIGROUP INC pharmaceutical preparations | 720 | 1.69% | 1.69% | $1.27M | Feb 12, 2025 | NEW |
SIMPLEX TRADING, LLC pharmaceutical preparations | 710 | 1.67% | 1.67% | $1.00M | Feb 11, 2025 | NEW |
ADVISOR GROUP HOLDINGS, INC. pharmaceutical preparations | 500 | 1.18% | 1.18% | $215,000 | Feb 7, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q4 2024 vs prior quarter
Q4 2024
0
Increased
+0 shares12
New Positions
first time holders0
Decreased
−0 shares17
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
-5
12 new / 17 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
KZIA insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Kazia Therapeutics Limited (KZIA) is primarily owned by institutional investors, who hold approximately 19.9% of total shares outstanding. Company insiders own approximately 1.43%, while retail and public investors account for the remaining 78.71%.
The largest institutional shareholder of Kazia Therapeutics Limited is MAI CAPITAL MANAGEMENT, holding approximately 139,208 shares — equal to 3.27% of outstanding shares — as of December 31, 2024.
A total of 12 institutional investors currently hold KZIA stock, with a combined institutional value of approximately $569,091 as of the most recent 13F filing period.
Frequently asked questions
KZIA ownershipKazia Therapeutics Limited (KZIA) is primarily owned by institutional investors, who hold approximately 19.9% of shares. The largest shareholder is MAI CAPITAL MANAGEMENT with a 3.27% stake. Company insiders hold 1.43%. Data sourced from SEC Form 13F as of December 31, 2024.